Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 331-345

  Fukudo, Masahide ^a   Yano, Ikuko ^a   Masuda, Satohiro ^a   Goto, Maki ^a   Uesugi, Miwa ^a   Katsura, Toshiya ^a   Ogura, Yasuhiro ^a   Oike, Fumitaka ^a   Takada, Yasutsugu ^a   Egawa, Hiroto ^a   Uemoto, Shinji ^a   Inui, Ken ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; TACROLIMUS;

ADULT; ALLOMETRY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG CLEARANCE; FEMALE; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHARMACOGENOMICS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENES, MDR; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; LIVING DONORS; MALE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RNA, MESSENGER; TACROLIMUS;

EID: 33749258379     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.06.008     Document Type: Article

References (41)

1. Todo S., Furukawa H., Jin M.B., and Shimamura T. Living donor liver transplantation in adults: outcome in Japan. Liver Transpl 6 Suppl 2 (2000) S66-S72
2. Kelly D., Jara P., Rodeck B., Lykavieris P., Burdelski M., Becker M., et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 364 (2004) 1054-1061
3. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43 (2004) 623-653
4. Wallemacq P.E., Furlan V., Möller A., Schäfer A., Stadler P., Firdaous I., et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 23 (1998) 367-370
5. Sam W.J., Aw M., Quak S.H., Lim S.M., Charles B.G., Chan S.Y., et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 50 (2000) 531-541
6. García Sánchez M.J., Manzanares C., Santos-Buelga D., Blázquez A., Manzanares J., Urruzuno P., et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 40 (2001) 63-71
7. Staatz C.E., Taylor P.J., Lynch S.V., Willis C., Charles B.G., and Tett S.E. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 72 (2001) 1056-1061
8. del Mar Fernández de Gatta M., Santos-Buelga D., Domínguez-Gil A., and García M.J. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 41 (2002) 115-135
9. Yasuhara M., Hashida T., Toraguchi M., Hashimoto Y., Kimura M., Inui K., et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27 (1995) 1108-1110
10. Fukatsu S., Yano I., Igarashi T., Hashida T., Takayanagi K., Saito H., et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57 (2001) 479-484
11. Hebert M.F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27 (1997) 201-214
12. Kaplan B., Lown K., Craig R., Abecassis M., Kaufman D., Leventhal J., et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 67 (1999) 333-335
13. Masuda S., Uemoto S., Hashida T., Inomata Y., Tanaka K., and Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68 (2000) 98-103
14. Hashida T., Masuda S., Uemoto S., Saito H., Tanaka K., and Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 69 (2001) 308-316
15. Thervet E., Anglicheau D., King B., Schlageter M.H., Cassinat B., Beaune P., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76 (2003) 1233-1235
16. Anglicheau D., Thervet E., Etienne I., Hurault De Ligny B., Le Meur Y., Touchard G., et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75 (2004) 422-433
17. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245-254
18. Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., De Meyer M., Eddour D.C., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147-154
19. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
20. Hesselink D.A., van Gelder T., van Schaik R.H., Balk A.H., van der Heiden I.P., van Dam T., et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 76 (2004) 545-556
21. Goto M., Masuda S., Kiuchi T., Ogura Y., Oike F., Okuda M., et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14 (2004) 471-478
22. Chowbay B., Cumaraswamy S., Cheung Y.B., Zhou Q., and Lee E.J. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13 (2003) 89-95
23. Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12 (2002) 451-457
24. Masuda S., Goto M., Fukatsu S., Uesugi M., Ogura Y., Oike F., et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther 79 (2006) 90-102
25. Uesugi M., Masuda S., Katsura T., Oike F., Takada Y., and Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 16 (2006) 119-127
26. Cogill J.L., Taylor P.J., Westley I.S., Morris R.G., Lynch S.V., and Johnson A.G. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 44 (1998) 1942-1946
27. Masuda S., Uemoto S., Goto M., Fujimoto Y., Tanaka K., and Inui K. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther 75 (2004) 352-361
28. Koch I., Weil R., Wolbold R., Brockmöller J., Hustert E., Burk O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30 (2002) 1108-1114
29. Saeki M., Saito Y., Nakamura T., Murayama N., Kim S.R., Ozawa S., et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 21 (2003) 653
30. van Schaik R.H., van der Heiden I.P., van den Anker J.N., and Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48 (2002) 1668-1671
31. Beal S.L., Boeckmann A.J., and Sheiner L.B. NONMEM users guides (1992), University of California at San Francisco, San Francisco
32. Sheiner L.B., and Beal S.L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9 (1981) 503-512
33. Evans W.E., and Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 429 (2004) 464-468
34. Antignac M., Hulot J.S., Boleslawski E., Hannoun L., Touitou Y., Farinotti R., et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 61 (2005) 409-416
35. Staatz C.E., Willis C., Taylor P.J., and Tett S.E. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72 (2002) 660-669
36. Fukudo M., Yano I., Fukatsu S., Saito H., Uemoto S., Kiuchi T., et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet 42 (2003) 1161-1178
37. Wallemacq P.E., and Verbeeck R.K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40 (2001) 283-295
38. Kamdem L.K., Streit F., Zanger U.M., Brockmöller J., Oellerich M., Armstrong V.W., et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51 (2005) 1374-1381
39. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62 (1997) 248-260
40. Christians U., Jacobsen W., Benet L.Z., and Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41 (2002) 813-851
41. Lemahieu W., Maes B., Verbeke K., Rutgeerts P., Geboes K., and Vanrenterghem Y. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 5 (2005) 1383-1391